Research Categories
- Anesthesia
- Arthroscopy
- Biologics/Biomaterials
- Cancer Devices
- Cardiovascular
- Cosmetic Devices
- Dental
- Diabetes
- Diagnostics
- Dialysis
- Drug Delivery
- Ear, Nose, Throat
- Endoscopy
- Gastrointestinal (GI)
- General Surgery
- Gynecology Devices
- Healthcare IT
- Hearing Devices
- Imaging
- Immunology
- In-Vitro Diagnostics
- Infusion Therapy
- Laparoscopy
- Minimally Invasive Surgery
- Neurology Devices
- Oncology
- Operating Room Equipment
- Ophthalmics Devices
- Orthopedics
- Patient Monitoring
- Peripheral Vascular
- Respiratory Devices
- Robotics & Navigation
- Sleep Apnea & Diagnostics
- Spine
- Stents
- Telehealth & Telemedicine
- Tissue Repair
- Urology
- Vascular Access
- Video Hi-Tech
- Women's Health
- Wound Care
Report Library
Showing 625–636 of 746 resultsSorted by latest
Immunology Drugs Market Report Suite | Europe | 2017-2023 | MedSuite (Includes 5 Reports)
The Europe immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market across the major 5 countries in Europe. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
more...Immunology Drugs Market Report Suite | Brazil | 2018-2024 | MedSuite (Includes 5 Reports)
The Japan and BRIC immunology drugs report provides market analysis, sizing, forecasts, and market shares of the immunology drugs. The report analyses key factors instrumental in changing the market scenario and provide a forecast of the future immunology market in Brazil, Russia, India and China. Key market players are profiled and a detailed view of their current strategic interests and a review on their financial performance has been provided.
more...Infusion Pump Market Analysis, Size, Trends | Global | 2018-2024 | MedCore
Industry Trends The infusion pump market is in the mature phase of its market cycle, but its potential to increase the spectrum of application, as well as a constant stream of technological and procedural innovation, allowed it to steadily grow in the past few years. This market includes large volume infusion pump, syringe infusion pump, […]
more...Ulcerative Colitis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Immunology Drugs Market Overview | Europe | 2018-2024 | MedView
The Europe immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics.
more...Ulcerative Colitis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis across the globe (12 countries), including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Rheumatoid Arthritis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis across the globe (12 countries), including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Psoriasis Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat psoriasis across the globe (12 countries), including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Crohn’s Disease Drug Market Analysis | Europe | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat Crohn’s disease across the globe (12 countries), including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ankylosing Spondylitis Drug Market Analysis | Global | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis across the globe (12 countries), including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Ulcerative Colitis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat ulcerative colitis outside the U.S. and Europe, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...Rheumatoid Arthritis Drug Market Analysis | Brazil | 2018-2024 | MedCore
This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis outside the U.S. and Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.
more...